Zymeworks Inc. (ZYME)

Price$24.04

Value ScoreD

Growth ScoreC

Momentum ScoreB

Favorite Metrics

Price vs S&P 500 (26W)-17.92%

Price vs S&P 500 (4W)0.64%

VGM Score45.49

Market Capitalization$1.78B

All Metrics

Book Value / Share (Quarterly)$2.22

P/TBV (Annual)7.43x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)-36.43%

Cash Flow / Share (Quarterly)$-1.05

Price vs S&P 500 (YTD)-16.86%

Net Profit Margin (TTM)-126.33%

EPS (TTM)$-1.37

10-Day Avg Trading Volume0.75M

EPS Excl Extra (TTM)$-1.37

Revenue Growth (5Y)22.13%

EPS (Annual)$-1.08

ROI (Annual)-30.22%

Net Profit Margin (5Y Avg)-231.32%

Cash / Share (Quarterly)$4.95

Revenue Growth QoQ (YoY)-91.90%

ROA (Last FY)-23.41%

Revenue Growth TTM (YoY)3.34%

EBITD / Share (TTM)$-1.46

ROE (5Y Avg)-30.36%

Operating Margin (TTM)-140.35%

Cash Flow / Share (Annual)$-0.47

P/B Ratio10.87x

P/B Ratio (Quarterly)11.29x

Net Income / Employee (Annual)$-307,300

EV / Revenue (TTM)18.87x

Net Interest Coverage (TTM)-96.25x

ROA (TTM)-25.19%

EV / EBITDA (TTM)7.24x

EPS Incl Extra (Annual)$-1.08

Current Ratio (Annual)5.88x

Quick Ratio (Quarterly)10.36x

3-Month Avg Trading Volume0.66M

52-Week Price Return98.19%

EV / Free Cash Flow (Annual)0.77x

Revenue / Employee (TTM)$307,800

Tangible BV / Share (Quarterly)$2.21

P/S Ratio (Annual)16.78x

Asset Turnover (Annual)0.31x

52-Week High$29.75

Operating Margin (5Y Avg)-244.90%

EPS Excl Extra (Annual)$-1.08

CapEx CAGR (5Y)-17.89%

Tangible BV CAGR (5Y)-7.14%

26-Week Price Return-10.00%

Quick Ratio (Annual)5.52x

13-Week Price Return-3.06%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)10.82x

Enterprise Value$1.53B

Revenue / Share Growth (5Y)12.68%

Asset Turnover (TTM)0.20x

Book Value / Share Growth (5Y)-16.71%

Revenue / Employee (Annual)$401,400

Pretax Margin (Annual)-75.26%

Cash / Share (Annual)$3.04

3-Month Return Std Dev43.81%

Net Income / Employee (TTM)$-388,800

ROE (Last FY)-30.22%

Net Interest Coverage (Annual)-726.00x

EPS Basic Excl Extra (Annual)$-1.08

P/FCF (TTM)158.92x

Receivables Turnover (TTM)5.55x

EV / Free Cash Flow (TTM)1.36x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-1.37

Receivables Turnover (Annual)3.51x

ROI (TTM)-37.79%

P/S Ratio (TTM)21.88x

Pretax Margin (5Y Avg)-229.54%

Revenue / Share (Annual)$1.41

Tangible BV / Share (Annual)$3.55

Forward P/E35.39x

Price vs S&P 500 (52W)73.82%

Year-to-Date Return-8.70%

5-Day Price Return-2.04%

EPS Normalized (Annual)$-1.08

ROA (5Y Avg)-21.12%

Net Profit Margin (Annual)-76.56%

Month-to-Date Return-4.34%

Cash Flow / Share (TTM)$3.17

EBITD / Share (Annual)$-1.18

Operating Margin (Annual)-87.34%

LT Debt / Equity (Annual)0.00x

ROI (5Y Avg)-30.35%

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-1.37

P/TBV (Quarterly)11.37x

P/B Ratio (Annual)7.39x

Pretax Margin (TTM)-127.94%

Book Value / Share (Annual)$3.57

Price vs S&P 500 (13W)-11.32%

Beta1.15x

P/FCF (Annual)13.57x

Revenue / Share (TTM)$1.09

ROE (TTM)-37.79%

52-Week Low$11.51

vGradeD

gGradeC

mGradeB

vgmGradeC

Show chart for

Earnings Surprise History

Q1 26-0.59est. -0.20

Analyst Recommendations

Mar 2026

Apr 2026

May 2026

Jun 2026

4.25

Industry Peers — Pharmaceuticals(550)

Symbol	Value Score	Growth Score	Momentum Score	Price
ZYMEZymeworks Inc.	D	C	B	$24.04
LLYEli Lilly & Co.	D	B	B	$1131.42
JNJJohnson & Johnson	D	C	B	$232.77
ABBVABBVIE INC.	D	C	C	$227.23
MRKMerck & Co., Inc.	C	C	B	$120.79
NVSNovartis AG	C	C	C	$149.16
AZNAstraZeneca PLC	D	B	C	$185.95
NVONovo-Nordisk A/S	B	B	B	$42.96
ABTAbbott Laboratories	C	C	D	$91.07
PFEPfizer Inc.	B	C	C	$26.04
BMYBristol-Myers Squibb Co.	B	C	B	$57.27

About

Zymeworks is a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics using its proprietary drug development platform. Its lead candidate, zanidatamab, is a HER2-targeted bispecific antibody currently in Phase 1/2 and pivotal clinical trials for solid tumors expressing HER2. The company also maintains a preclinical pipeline in oncology and other therapeutic areas.